Nasdaq Moves to Delist Alaunos Therapeutics Over Equity Shortfall
TCRT is trading near its 52-week low of $0.719 (14% above the low).
Summary
Nasdaq has initiated delisting proceedings against Alaunos Therapeutics for failing to maintain the $2.5 million minimum stockholders' equity requirement. The company will request a hearing to stay the delisting while it explores strategic alternatives to regain compliance.
Key Events · Legal and Risk Events · TCRT
-
Nasdaq Delisting Notice Received
On October 5, 2026, Nasdaq notified Alaunos Therapeutics that its securities are subject to delisting for failing to maintain the $2.5 million minimum stockholders' equity required under Listing Rule 5550(b)(1).
-
Hearing Request to Stay Delisting
The company plans to timely request a hearing before the Nasdaq Hearings Panel, which will stay any suspension or delisting action at least until the hearing is held and any extension granted expires.
-
Strategic Alternatives Under Evaluation
Alaunos is working with a financial advisor to complete one or more potential transactions intended to strengthen its financial position and regain compliance with Nasdaq listing requirements.
-
Precarious Financial Position
As of the last 10-Q, stockholders' equity was $1.288 million and cash was $0.35 million, both well below Nasdaq's minimum thresholds, reinforcing the going concern risk.
Analysis · TCRT · Life Sciences
Nasdaq has formally initiated delisting proceedings against Alaunos Therapeutics after the company failed to maintain the required $2.5 million minimum stockholders' equity. The company received the delisting notice on October 5, 2026, and plans to request a hearing before the Nasdaq Hearings Panel, which would temporarily stay any suspension or delisting action. Alaunos is simultaneously exploring strategic alternatives with a financial advisor to strengthen its financial position and regain compliance. With stockholders' equity of only $1.288 million as of the last 10-Q and a critical cash position of $0.35 million, the company faces an existential listing threat. The delisting notice is a major negative event that could force the stock to trade on less liquid over-the-counter markets, significantly reducing investor access and institutional interest.
How filings like this one have moved
In the 30 days to Oct 9, 2026, 44% of the 307 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.58%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, TCRT was trading at $0.82 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.3M. The 52-week trading range was $0.72 to $4.59. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.